Bicalutamide (150 mg) versus placebo as immediate therapy alone or as adjuvant to therapy with curative intent for early nonmetastatic prostate cancer: 5.3-year median followup from the Scandinavian Prostate Cancer Group Study Number 6.

@article{Iversen2004BicalutamideM,
  title={Bicalutamide (150 mg) versus placebo as immediate therapy alone or as adjuvant to therapy with curative intent for early nonmetastatic prostate cancer: 5.3-year median followup from the Scandinavian Prostate Cancer Group Study Number 6.},
  author={Peter Bindslev Iversen and Jan Johansson and P{\"a}r Lodding and Olavi Lukkarinen and Per I. Lundmo and Peter Klarskov and Teuvo L J Tammela and Ilker Tasdemir and Tom H. Morris and Kevin F Staveley-O' Carroll},
  journal={The Journal of urology},
  year={2004},
  volume={172 5 Pt 1},
  pages={
          1871-6
        }
}
PURPOSE We evaluated the benefits of adding 150 mg bicalutamide to standard care, that is radical prostatectomy, radiotherapy or watchful waiting (WW), in patients with localized or locally advanced prostate cancer. MATERIALS AND METHODS A total of 1,218 men with T1-4, M0, any N prostate cancer were recruited from 62 Scandinavian centers and randomized 1:1 to 150 mg bicalutamide or placebo plus standard care. Primary end points were progression-free survival (PFS) and overall survival… CONTINUE READING
BETA

Similar Papers

Citations

Publications citing this paper.
SHOWING 1-10 OF 28 CITATIONS

Das Lokalrezidiv des Prostatakarzinoms: Hormontherapie

VIEW 10 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED